Dropsense
Dropsense is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Dropsense.
Frequently Asked Questions
Who founded Dropsense?
Dropsense was founded by Jeremy Fiance (Co-Founder).
Dropsense is a company.
Key people at Dropsense.
Dropsense was founded by Jeremy Fiance (Co-Founder).
Dropsense was founded by Jeremy Fiance (Co-Founder).
Key people at Dropsense.
DropSens (also referred to as Metrohm DropSens or Dropsense in some contexts) is a Spanish technology company founded in 2006, specializing in the design, fabrication, and commercialization of electrochemical screen-printed devices used as (bio)sensors, along with portable scientific instrumentation for electrochemistry research.[1][2][4] Acquired by Swiss firm Metrohm in 2017, it serves researchers, clinicians, and industries in environmental, agri-food, and in vitro diagnostics by providing flexible, user-friendly tools like screen-printed electrodes, potentiostats, and custom sensors for detecting analytes such as lactate.[1][2] The company operates globally, distributing to over 60 countries, holds ISO 9001 and ISO 13485 certifications for medical device manufacturing, and engages in 4 research projects annually, including EU-funded initiatives like H2020 and Eurostars.[1]
A separate entity named Dropsense develops a consumer-focused low blood sugar alert system leveraging sensing, mobile tech, and machine learning for diabetes management, though details on its operations, scale, or traction are limited in available data.[3][5] Given the prominence of DropSens in electrochemical innovation, this overview prioritizes it as the core match for "Dropsense," a common shorthand.
DropSens was established in 2006 in Asturias, Spain, as an innovative technology-based firm focused on electrochemistry tools.[1][4] It evolved from a startup emphasizing screen-printed electrodes into a key player in (bio)sensors and portable instruments, gaining traction through R&D collaborations and global distribution.[1][2] The 2017 acquisition by Metrohm, a Swiss industry giant, provided enhanced resources like advanced characterization tools (SEM, TEM, AFM, XPS) and expanded its reach into clinical and regulatory-compliant markets.[1] Pivotal moments include ISO 13485 certification for medical sensors, participation in high-profile EU projects (e.g., FP7, H2020, Eurostars), and annual attendance at 20+ international conferences, building early credibility in research-to-product translation.[1]
The Dropsense diabetes alert system emerged as a distinct venture harnessing modern sensors and AI for affordable hypoglycemia detection, but founder details and early milestones remain undisclosed in public records.[3][5]
DropSens stands out in the electrochemistry sector through:
For the Dropsense blood sugar system, key edges include affordability and seamless integration of sensing, mobile apps, and machine learning for non-invasive alerts, targeting diabetes patients underserved by traditional monitors.[3][5]
DropSens rides the wave of point-of-care diagnostics and portable analytics, fueled by demand for rapid, on-site testing in healthcare, environment, and food safety amid rising chronic diseases and sustainability needs.[1][2] Timing aligns with EU funding for sensor tech (H2020-era projects) and post-2017 Metrohm synergies, amplifying influence in biosensor standardization.[1] Market forces like miniaturization of lab tools and regulatory pushes for ISO-compliant devices favor its portable potentiostats and custom electrodes, positioning it as an enabler for research-to-market translation in electrochemistry.[1][2] It influences the ecosystem by partnering in international consortia, disseminating via conferences, and supporting scalable medtech, indirectly boosting startups in wearables and IoT sensing.
Dropsense taps AI-driven personal health monitoring trends, addressing diabetes management gaps where continuous glucose systems are costly; its ML-enhanced alerts could democratize access amid growing wearable healthtech adoption.[3][5]
DropSens is poised for expansion in decentralized testing and biosensor AI integration, with trends like edge computing and multiplexed analytics enhancing its portable tools for real-time diagnostics.[1][2] Expect deeper medtech penetration via ISO expertise and Metrohm's network, potentially capturing shares in wearables or enviro-sensors as global health regs tighten. Dropsense could scale its hypoglycemia system through consumer partnerships, riding telehealth booms. Both exemplify sensing tech's shift from labs to everyday impact—DropSens as the B2B enabler, Dropsense as the direct-to-patient innovator—shaping a more proactive biotech landscape.
